Masha Fridkis-Hareli, M.Sc., Ph.D., is an immunologist, consultant and inventor with over 20 years of experience in academia and industry. She is Founder and President of ATR, a scientific consulting and laboratory services company providing expertise in immunoassay development for discovery and pre-clinical drug development phases. During her post-doctoral training at Harvard University, she designed and developed a group of novel compounds for treatment of autoimmune diseases, which advanced into Phase II clinical trials. Dr. Fridkis-Hareli served as Principal Investigator of the Molecular Immunology Foundation at the Dana Farber Cancer Institute, and held positions with increasing responsibilities at a number of biotechnology companies and a global CRO.
In the role of Associate Scientific Director, Dr. Fridkis-Hareli contributed to discovery and development of Taligen Therapeutics’ drug pipeline leading to acquisition by Alexion Pharmaceuticals. Her areas of expertise include in vitro pharmacology, protein- and cell-based assays, flow cytometry, and preclinical immunotoxicology. Dr. Fridkis-Hareli is a co-author of over 100 publications and 17 issued patents. She is an Adjunct Professor at several local universities’ graduate biopharmaceutical programs, including Harvard Extension School, Northeastern University, and Worcester Polytechnic Institute. In addition to her professional affiliations, Dr. Fridkis-Hareli is actively involved on boards of several professional organizations, which include serving as a co-chair of the Drug Discovery Working Group at the Massachusetts Biotechnology Council and as a Past President of the Association for Women in Science in Massachusetts.
Dr. Fridkis-Hareli holds a B.A. in Biology from Technion, Israeli Institute of Technology; an M.Sc. in Molecular Microbiology from the Hebrew University; and a Ph.D. in Immunology from the Weizmann Institute of Science, Israel.
